Equity in Cancer Care: Measuring Disparities in Canada
Summary
This study looks at how a person’s race, ethnicity, and social background can affect their cancer care and recovery. We know that people from different racial and ethnic groups sometimes have different experiences and outcomes after a cancer diagnosis. For example, some South Asian patients with head and neck cancer have lower survival rates than others, even when they receive similar treatment.
We want to better understand why these differences happen and how factors such as where someone lives, their immigration background, or their access to healthcare may play a role.
To do this, the study has two parts. In the first part, we will look at existing health data from people across Canada who have had cancer to see if there are patterns or differences in care or outcomes. In the second part, we will talk with people who have experienced cancer care to learn about their personal experiences in the healthcare system.
By combining both parts, this study aims to create a clearer picture of how race and ethnicity influence cancer care and outcomes in Canada.
Eligibility
Eligible ages: 18 to 80
Inclusion criteria:
Part 1 – A Retrospective Cohort Study: For this part, we will use existing health data from adults in Canada who have been diagnosed with one of the ten most common types of cancer. This study uses existing records; no one will be contacted directly or asked to take part.
Part 2 – A Qualitative Study: For this part, adults who have been diagnosed with one of the ten most common cancers in Canada within the last five years may take part. Participants must have received cancer care in Canada and be able to take part in a focus group/interview. We will include people from different racial and ethnic backgrounds, places of residence (for example, rural or urban areas), and immigration experiences to make sure we hear from a wide range of perspectives.
Exclusion criteria:
1. Patients younger than 18 years old.
2. Patients who have not had cancer.
Participate
Additional information
Contact information
K2I Lab, Cumming School of Medicine (Lab information) University of Calgary Email: k2i@ucalgary.ca Phone: (403) 210-5463 Dr. Khara Sauro, PhD (Principal Investigator) Cumming School of Medicine, University of Calgary Email: kmsauro@ucalgary.ca Phone: 403.210.5463
Principal investigator:
Khara Marissa Sauro
Clinical trial:
No
REB-ID:
HREBA.CC-25-0388